SCHEMBL24220752

SCHEMBL24220752

CC(C)(C)OC(=O)N1CCC[C@H](N(CC(=O)O)C(=O)C(F)(F)F)C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.45
ALDH1A1 P00352 1/20 0.45
MAPT P10636 1/20 0.45
KMT2A Q03164 1/20 0.45
USP30 Q70CQ3 4/20 0.40
HPGD P15428 1/20 0.40
JAK2 O60674 1/20 0.39
JAK1 P23458 1/20 0.39
HDAC4 P56524 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
BACE1 P56817 2/20 0.37
PRMT5 O14744 2/20 0.37
HSD11B1 P28845 1/20 0.37
ACKR3 P25106 1/20 0.37
CTSD P07339 1/20 0.37
WDR77 Q9BQA1 1/20 0.36
GPR119 Q8TDV5 1/20 0.36
EPHX1 P07099 1/20 0.36
GLS O94925 1/20 0.36
TACR1 P25103 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21964050 0.91 MEN1 (0.46) MEN1ALDH1A1MAPTKMT2AUSP30
SCHEMBL21964052 0.91 MEN1 (0.46) MEN1ALDH1A1MAPTKMT2AUSP30
SCHEMBL21964129 0.89 MEN1 (0.42) MEN1ALDH1A1MAPTKMT2AUSP30
SCHEMBL24220741 0.87 ALDH1A1 (0.42) MEN1ALDH1A1MAPTKMT2AUSP30
SCHEMBL28594993 0.86 MEN1 (0.46) MEN1ALDH1A1MAPTKMT2AUSP30
SCHEMBL24220733 0.86 MEN1 (0.46) MEN1ALDH1A1MAPTKMT2AUSP30
SCHEMBL21964124 0.83 USP30 (0.47) MEN1ALDH1A1MAPTKMT2AUSP30
SCHEMBL24220798 0.83 MEN1 (0.40) MEN1ALDH1A1MAPTKMT2AUSP30
SCHEMBL28594990 0.83 MEN1 (0.40) MEN1ALDH1A1MAPTKMT2AUSP30
SCHEMBL555509 0.82 MAPT (0.49) MEN1ALDH1A1MAPTKMT2AUSP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220023281-A1 HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS THE UNIVERSITY OF SHEFFIELD (GB) 2022-01-27 US disclosed
CN-113227091-A As AM2Heterocyclic spiro-compounds as receptor inhibitors 谢菲尔德大学 2021-08-06 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220023281-A1 HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS MC2R, AGTR2, AGTR1 MEN1 6/4885ALDH1A1 1456/4885MAPT 4581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.